Supriya Lifescience Restricted IPO GMP, Allotment Date, Standing, Value

The Mumbai-primarily based mostly completely energetic prescribed drugs components (APIs) producer, Supriya Lifescience, is about to open its Supriya Lifescience Restricted IPO GMP on December 16. The corporate produces 38 APIs centered on totally different therapeutic segments comparable to antihistamines, ache relievers, anesthetics, nutritional vitamins, anti-asthmatic and anti-allergic medication. Supriya Lifescience merchandise had been exported to 86 nations and 1,296 purchasers in FY21. The company has API enterprise in Europe, Latin America, Asia, and North America. He’s seeking to elevate 700 crores via the IPO, which consists of a brand new challenge of 200 crore and a promote provide of ₹ 500 crore.

Supriya Lifescience Restricted IPO GMP

  • Supriya Lifescience manufactures Energetic Pharmaceutical Components (APIs). It produces 38 components centered on therapeutic segments comparable to ache relievers, anesthetics, antiallergics,
  • It seeks to boost 700 crores via the IPO which consists of a brand new challenge of ₹ 200 crore and a promote provide of ₹ 500
  • The corporate’s IPO will open and shut on December It has a worth vary of 265-274 per share.
  • Particular person traders can bid on a minimal of 54 shares with a worth of 14,796 per

Objects of the Difficulty

  • Financing of the Firm’s funding expenditure necessities;
  • Compensation and/or prepayment, in complete or partly, of sure loans utilized by the Firm and
  • Normal business functions

Supriya Lifescience Limited IPO

Supriya Lifescience Restricted IPO Particulars

Objects of the problem
  • Funding New CAPEX requirement of the corporate
  • Compensation/Prepayment of present Borrowing of the corporate.
  • Normal company functions.
Difficulty Dimension
  • Whole challenge dimension -Rs. 700 Cr.
  • Provide for Sale – Rs. 500 Cr.
  • Contemporary Difficulty – Rs. 200 Cr.
Face worth Rs.2.00 Per Fairness Share
Difficulty Value Rs. 265 – Rs.274
Bid Lot 54 shares
Itemizing at  BSE, NSE
Difficulty Opens: 16thDec, 2022 – 20th Dec, 2022
QIB 75% of Web Difficulty Provide
Retail 10% of Web Difficulty Provide
NIB 15% of Web Difficulty Provide

Necessary Dates Related With The IPO

Value Band ₹265 To ₹274
IPO Open Date December 16
IPO Shut Date December 20
Allotment Date December 23
Initiation Of Refunds December 24
Credit score Of Shares To Demat Account December 27
IPO Itemizing Date December 28
Minimal Lot 54

The web proceeds of the brand new challenge will probably be used for capital expenditures, debt reimbursement, and common enterprise functions.

Supriya Lifescience IPO Provisional Timetable

The Supriya Lifescience IPO open date is Dec 16, 2022, and the close to date is Dec 20, 2022. The issue may additionally moreover record on Dec 28, 2022.

IPO Open Date Dec 16, 2022
IPO Shut Date Dec 20, 2022
Foundation of Allotment Date Dec 23, 2022
Initiation of Refunds Dec 24, 2022
Credit score of Shares to Demat Account Dec 27, 2022
IPO Itemizing Date Dec 28, 2022

Supriya Lifescience IPO Date And Value Band

 IPO Open:  16 December 2022
 IPO Shut:  20 December 2021
 IPO Dimension:  Approx ₹700 Crores
 Contemporary Difficulty:  Approx ₹200 Crores
 Provide for Sale:  Approx ₹500 Crores
 Face Worth:  ₹2 Per Fairness Share
 Value Band:  ₹265 to ₹274 Per Share
 Itemizing on:  BSE & NSE
 Retail Quota:  10%
 QIB Quota:  75%
 NII Quota:  15%
 Low cost:  ₹- for Retail Buyers

Firm’s Deal with

Supriya Lifescience Restricted

207/208, Udyog Bhavan, Sonawala Street,

Goregaon–East, Mumbai – 400063,

Maharashtra, India

Tel: +91-22-40332727

Contact Particular person: Shweta Shivdhari Singh

Firm Secretary and Compliance Officer

Tel: +91-22-40332727

E-mail: [email protected]

Web site:

Company Identification Quantity: U51900MH2008PLC180452OUR

Supriya Lifescience Firm Monetary Report (Cr)

Yr Income Expense P&L
2021 ₹25,993.50 ₹23,694.00 ₹1,520.73
2020 ₹21,762.53 ₹21,377.81 ₹230.24
2019 ₹21,591.22 ₹21,037.06 ₹851.33

Supriya Lifescience Restricted IPO Threat Elements

  • The corporate generates a good portion of its income from just a few gamers, so a lack of prospects can have a major affect on the corporate’s income.
  • The corporate operates in a extremely regulated business and should adhere to the security and manufacturing laws of varied companies, so any deficiency in manufacturing requirements might preclude their

Supriya Lifescience Restricted IPO Outlook

Supriya Lifesciences Restricted is the biggest exporter of chlorpheniramine maleate, Ketamine hydrochloride, and India salbutamol sulfate, supplies their product in India and International Pharma Firm, about 70% of revenues come from the export market wherein they supply

Supriya’s facility is licensed by the entire world’s high pharmaceutical companies and has sturdy RandD functionality and often enters area of interest merchandise.

The corporate has proven sturdy monetary efficiency over the previous three years and this pattern is anticipated to proceed as a consequence of China’s plus one coverage and the federal government’s initiative to grow to be self-sufficient within the API house.

On the highest worth bracket of 274,274, the corporate will commerce at a P / E of 17.81x after the issuance of FY21E, which is consistent with different API corporations, so we advocate that you simply SIGN UP for this Supriya Lifescience Restricted IPO GMP.

Source link

Leave a Comment